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httpPreoperative symptom type inﬂuences the 30-day
perioperative outcomes of carotid endarterectomy
and carotid stenting in the Society for Vascular
Surgery Vascular Registry
Patrick J. Geraghty, MD,a Thomas E. Brothers, MD,b David L. Gillespie, MD,c Gilbert R. Upchurch, MD,d
Michael C. Stoner, MD,e Flora S. Siami, MPH,f Christopher T. Kenwood, MS,f and Philip P. Goodney, MD,g
St. Louis, Mo; Charleston, SC; Fall River and Watertown, Mass; Charlottesville, Va; Greenville, NC; and
Lebanon, NH
Objective: The objective of this study was to determine the effect of presenting symptom types on 30-day periprocedural
outcomes of carotid endarterectomy (CEA) and carotid artery stenting (CAS) in contemporary vascular practice.
Methods: Retrospective review was undertaken of the Society for Vascular Surgery Vascular Registry database subjects who
underwent CEA or CAS from 2004 to 2011. Patients were grouped by discrete 12-month preprocedural ipsilateral
symptom type: stroke, transient ischemic attack (TIA), transient monocular blindness (TMB), or asymptomatic (ASX).
Risk-adjusted odds ratios (ORs) were used to compare the likelihood of the 30-day outcomes of death, stroke, and
myocardial infarction (MI) and the composite outcomes of death D stroke and death D stroke D MI.
Results: Symptom type signiﬁcantly inﬂuences risk-adjusted 30-day outcomes for carotid intervention. Presentation with
stroke predicted the poorest outcomes (deathD strokeDMI composite: OR, 1.3; 95% conﬁdence interval [CI], 0.83-2.03
vs TIA; OR, 2.56; 95% CI, 1.18-5.57 vs TMB; OR, 2.12; 95% CI, 1.46-3.08 vs ASX), followed by TIA (deathD strokeD
MI composite: OR, 1.97; 95% CI, 0.91-4.25 vs TMB; OR, 1.63; 95% CI, 1.14-2.33 vs ASX). For both CAS and CEA
patients, presentationwith stroke orTIApredicted a higher risk of periprocedural stroke than inASXpatients. Presentation
with stroke predicted higher 30-day risk of death with CAS but not with CEA. MI rates were not affected by presenting
symptom type. The 30-day outcomes for the TMB and ASX patient groups were equivalent in both treatment arms.
Conclusions: Presenting symptom type signiﬁcantly affects the 30-day outcomes of both CAS and CEA in contemporary
vascular surgical practice. Presentation with stroke and TIA predicts higher rates of periprocedural complications, whereas
TMB presentation predicts a periprocedural risk proﬁle similar to that of ASX disease. (J Vasc Surg 2014;60:639-44.)In addition to prior completed ipsilateral stroke, monocular blindness (TMB, also known as amaurosis
hemispheric transient ischemic attack (TIA) ipsilateral to
signiﬁcant carotid bifurcation stenosis has long been
known to predict subsequent ipsilateral stroke and excess
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an elevated risk of subsequent stroke, although less than
that described for TIA.3
The North American Symptomatic Carotid Endarter-
ectomy Trial (NASCET) ﬁrmly established the beneﬁt of
carotid endarterectomy (CEA) for symptomatic moderate
to severe carotid stenoses.4,5 NASCET also added to our
knowledge of the natural history of symptomatic carotid
disease; analysis of the medical treatment arm of NASCET
demonstrated a higher 2-year risk of stroke for patients pre-
senting with hemispheric TIA (43.5% 6 6.7%) in compar-
ison to TMB (16.6% 6 5.6%).6 Separate examination of
surgical results from NASCET showed that procedural
stroke outcomes were poorer for patients presenting with
hemispheric TIA rather than TMB,7 conﬁrming the ﬁnd-
ings of earlier investigators.8
Yet even as NASCET and the Asymptomatic Carotid
Atherosclerosis Study9 established the primacy of CEA for
stroke reduction in symptomatic and asymptomatic lesions,
early experiences with angioplasty and stent placement for
carotid disease were being reported.10,11 During the next
decade, carotid artery stenting (CAS) was compared with
CEA in randomized trials ranging from the Stenting and
Angioplasty with Protection in Patients with High Risk
for Endarterectomy (SAPPHIRE) study to the more639
Table I. Demographics and medical history
Mutually exclusive symptom in last 12 months
P valueaStroke (n ¼ 947) TIA (n ¼ 1449) TMB (n ¼ 508) ASX (n ¼ 5736)
Age, years (range) 69.7 (29-94) 71.6 (18-98) 69.7 (47-94) 71.2 (39-95) <.0001
Gender, male (%) 61.1% (579/947) 59.8% (866/1449) 68.3% (347/508) 58.2% (3336/5736) <.0001
Race, white 87.9% (832/947) 92.8% (1344/1449) 92.7% (471/508) 93.7% (5374/5736) <.0001
Ethnicity, Hispanic 4.6% (44/947) 3.1% (45/1449) 2.8% (14/508) 3.2% (185/5736) .1100
Coronary artery disease 45.3% (429/947) 49.6% (718/1449) 47.8% (243/508) 54.4% (3121/5736) <.0001
MI 16.7% (158/947) 16.7% (242/1449) 16.9% (86/508) 19.2% (1104/5736) .0437
Valvular heart disease 6.1% (58/947) 7.5% (109/1449) 6.5% (33/508) 7.6% (438/5736) .3401
Cardiac arrhythmia 12.2% (116/947) 13.0% (188/1449) 12.8% (65/508) 14.0% (805/5736) .3684
Congestive heart failure 10.7% (101/947) 10.0% (145/1449) 9.6% (49/508) 10.0% (574/5736) .9184
Hypertension 84.6% (801/947) 83.8% (1214/1449) 76.4% (388/508) 84.7% (4861/5736) <.0001
Diabetes 36.3% (344/947) 32.2% (467/1449) 28.0% (142/508) 32.7% (1877/5736) .0118
Chronic obstructive pulmonary disease 18.0% (170/947) 19.3% (280/1449) 22.6% (115/508) 17.7% (1013/5736) .0285
Chronic renal failure 4.0% (38/947) 3.5% (50/1449) 2.0% (10/508) 3.3% (192/5736) .2294
Peripheral vascular disease 33.5% (317/947) 37.6% (545/1449) 36.0% (183/508) 43.9% (2520/5736) <.0001
Current or past smoker 59.6% (564/947) 58.5% (847/1449) 66.5% (338/508) 60.9% (3494/5736) .0120
Cancer 15.2% (144/947) 16.9% (245/1449) 19.1% (97/508) 14.2% (816/5736) .0037
Coagulopathy 1.5% (14/947) 1.4% (20/1449) 0.6% (3/508) 1.3% (72/5736) .5013
ASA grade
#3 88.1% (834/947) 91.5% (1326/1449) 92.9% (472/508) 92.1% (5282/5736) .0004
>3 11.9% (113/947) 8.5% (123/1449) 7.1% (36/508) 7.9% (454/5736)
New York Heart Association class
#2 93.7% (887/947) 92.1% (1335/1449) 93.3% (474/508) 93.7% (5372/5736) .2147
>2 6.3% (60/947) 7.9% (114/1449) 6.7% (34/508) 6.3% (364/5736)
Aspirin 79.3% (751/947) 84.9% (1230/1449) 82.9% (421/508) 84.9% (4872/5736) .0001
Clopidogrel 46.5% (440/947) 50.0% (725/1449) 51.0% (259/508) 39.0% (2235/5736) <.0001
Aspirin or clopidogrel 88.4% (837/947) 92.0% (1333/1449) 92.1% (468/508) 90.3% (5179/5736) .0146
Age $80 years 20.3% (192/947) 23.2% (336/1449) 18.3% (93/508) 19.5% (1117/5736) .0115
Embolic protection (CAS only) 95.8% (322/336) 97.0% (554/571) 97.9% (184/188) 98.0% (1751/1787) .0992
ASA, American Society of Anesthesiologists; ASX, asymptomatic; CAS, carotid artery stenting; MI, myocardial infarction; TIA, transient ischemic attack;
TMB, transient monocular blindness.
aP value for age was found by analysis of variance. All others found by c2 tests.
Table II. Distribution by exclusive presenting symptom type and etiology
Etiology Stroke, No. (%) TIA, No. (%) TMB, No. (%) ASX, No. (%) Total, No. (%)
CEA patients
Atherosclerosis 604 862 313 3904 5683 (98.7)
Radiation 0 1 2 3 6 (0.1)
Restenosis 7 15 5 42 69 (1.2)
Total 611 (10.6) 878 (15.3) 320 (5.5) 3949 (68.6) 5758 (100)
CAS patients
Atherosclerosis 293 413 140 1202 2048 (71.1)
Radiation 10 24 16 91 141 (5.9)
Restenosis 33 134 32 494 693 (24.0)
Total 336 (11.7) 571 (19.8) 188 (6.5) 1787 (62.0) 2882 (100)
ASX, Asymptomatic; CAS, carotid artery stenting; CEA, carotid endarterectomy; TIA, transient ischemic attack; TMB, transient monocular blindness.
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arterectomy vs Stenting Trial (CREST).12,13 Both trials
enrolled asymptomatic and symptomatic patients, and their
publication has provided further insight into the compara-
tive beneﬁts of CAS and CEA. However, neither study
examined the relationship of presenting symptom type
(stroke, TIA, or TMB) to procedural outcomes.
The Society for Vascular Surgery Vascular Registry
(SVS-VR) carotid module collected demographic, proce-
dural, and outcomes data from contributing centers for
CEA and CAS from 2004 through 2011. By the nature ofregistry design, patients entered into the SVS-VR are un-
matched, yet risk-adjusted data from this “real-world” expe-
rience provide valuable insight into current vascular surgical
outcomes.14Using the SVS-VR,we sought to determine the
effect of presenting symptom type on early outcomes of
CEA and CAS in contemporary vascular practice.
METHODS
The derivation of 30-day periprocedural outcomes
data from the SVS-VR, inclusive of procedural and predis-
charge data, has previously been reported.14 All registry
Table III. Unadjusted event rates by procedure and presenting symptom type
Thirty-day
adverse event
CAS patients
P valuea
Symptom in last 12 months (mutually exclusive)
Stroke ipsilateral (n ¼ 336) TIA ipsilateral (n ¼ 571) TMB ipsilateral (n ¼ 188) ASX (n ¼ 1787)
Death 6.3% (21/336) 1.1% (6/571) 0.5% (1/188) 1.3% (24/1787) <.0001
Stroke 8.6% (29/336) 7.9% (45/571) 3.2% (6/188) 3.2% (57/1787) <.0001
MI 1.2% (4/336) 1.2% (7/571) 1.6% (3/188) 1.1% (20/1787) .8652
Death þ stroke þ MI 11.6% (39/336) 9.6% (55/571) 4.8% (9/188) 4.9% (88/1787) <.0001
Death þ stroke 11.0% (37/336) 8.4% (48/571) 3.2% (6/188) 4.3% (77/1787) <.0001
Thirty-day
adverse event
CEA patients
P valuea
Symptom in last 12 months (mutually exclusive)
Stroke ipsilateral (n ¼ 611) TIA ipsilateral (n ¼ 878) TMB ipsilateral (n ¼ 320) ASX (n ¼ 3949)
Death 1.8% (11/611) 0.8% (7/878) 0.0% (0/320) 0.8% (30/3949) .0277
Stroke 4.6% (28/611) 3.3% (29/878) 1.6% (5/320) 1.6% (64/3949) <.0001
MI 0.8% (5/611) 1.6% (14/878) 0.9% (3/320) 1.2% (49/3949) .6213
Death þ stroke þ MI 6.7% (41/611) 5.0% (44/878) 2.5% (8/320) 3.1% (124/3949) <.0001
Death þ stroke 6.2% (38/611) 4.0% (35/878) 1.6% (5/320) 2.2% (87/3949) <.0001
ASX, Asymptomatic; CAS, carotid artery stenting; CEA, carotid endarterectomy; MI, myocardial infarction; TIA, transient ischemic attack; TMB, transient
monocular blindness.
Events were deﬁned as any event occurring intraoperatively, before discharge, or between discharge and 30 days. The event rates in the table are per patient.
aP values were based on Fisher exact test.
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day outcomes reporting were identiﬁed. For clarity of
comparison, carotid procedures undertaken for athero-
sclerotic, radiation-induced, or restenotic lesions of the
carotid bifurcation and internal carotid artery were
included, but procedures undertaken for trauma, dissec-
tion, or unspeciﬁed causes were excluded. Procedures un-
dertaken only on the common carotid or external carotid
arteries were excluded. CEA and CAS patients were
grouped by discrete preprocedural ipsilateral symptom
type occurring within the 12 months before intervention:
stroke, TIA, TMB, or asymptomatic (ASX). Patients
reporting more than one symptom (eg, TIA and stroke)
were excluded from analysis. Risk-adjusted odds ratios
(ORs) were used to compare the likelihood of the
30-day outcomes of death, stroke, and myocardial infarc-
tion (MI) and the composite outcomes of death þ stroke
and death þ stroke þ MI.
Statistical methods. Descriptive statistical compari-
sons were conducted with c2 tests for categorical variables
and analysis of variance for continuous variables. Descrip-
tive statistics are listed as mean 6 standard deviation for
continuous variables and percentage (frequency) for cate-
gorical variables. Outcomes analyses comparing across
symptom groups were conducted in subsets of the cohort
with the Fisher exact test for discrete/categorical data.
Adjusted ORs found through multivariable logistic regres-
sion were used to compare the selected outcomes measures
between the symptom-deﬁned groups. Adjusted ORs for
the multiple symptom group comparisons were adjusted for
signiﬁcant baseline factors that were retained after applying
backwards elimination methods. Differences in multiplesymptom group comparisons were considered signiﬁcant if
P < .0083 (using a Bonferroni correction factor of 6). All
other differences were considered signiﬁcant if P < .05. All
statistical analyses were performed by New England
Research Institute (NERI, Watertown, Mass) with SAS
Statistical Software (Cary, NC).
All data entered into the SVS-VR are fully compliant
with the Health Insurance Portability and Accountability
Act regulations and are auditable. All data reports and an-
alyses performed include only de-identiﬁed and aggregated
data. NERI maintains the online database, and funding for
the administration and database management of the
Vascular Registry has been provided by the Society for
Vascular Surgery.
RESULTS
A total of 5758 CEA procedures and 2882 CAS pro-
cedures from the SVS-VR met the speciﬁed inclusion
criteria. Demographics and medical history for the
exclusive presenting symptom groups (Table I) reﬂect
the heterogeneity of these unmatched registry popula-
tions. The CAS treatment group contains higher per-
centages of interventions for restenosis and
postradiation changes than the CEA group does
(Table II), consistent with this technique’s ability to
avoid the surgical challenges associated with the hostile
or previously operated on neck. Unadjusted event rates
for CAS and CEA procedures, delineated by presenting
symptom type, are displayed in Table III. Although
certain unadjusted event rates in Table III are compel-
ling (such as the 11.6% periprocedural incidence of the
composite death þ stroke þ MI in patients presenting
Table IV. Risk-adjusted bivariate comparison of outcomes based on presenting symptom types within the carotid artery
stenting (CAS) treatment group
CAS: Multivariable (adjusted) logistic models
Ipsilateral symptom
Thirty-day
outcome
Comparison
group
Reference
group OR 95% CI P value Adjusted covariates
Death/stroke/
MI outcome
Stroke vs TIA 1.08 0.69-1.71 .7274 Controls for age, white race, diabetes, ASA
grade, clopidogrel, and CPD use
vs TMB 2.03 0.95-4.37 .0689
vs ASX 2.30 1.52-3.47 <.0001a
TIA vs TMB 1.88 0.90-3.92 .0941
vs ASX 2.12 1.48-3.04 <.0001a
TMB vs ASX 1.13 0.55-2.30 .7386
Death/stroke
outcome
Stroke vs TIA 1.16 0.72-1.86 .5481 Controls for age, white race, diabetes, ASA
grade, aspirin, clopidogrel, and CPD use
vs TMB 2.88 1.17-7.07 .0209
vs ASX 2.43 1.58-3.73 <.0001a
TIA vs TMB 2.49 1.04-5.99 .0412
vs ASX 2.10 1.43-3.08 .0002a
TMB vs ASX 0.84 0.36-1.98 .6933
Death outcome Stroke vs TIA 5.21 2.04-13.33 .0006a Controls for ASA grade, aspirin, and CPD use
vs TMB 10.03 1.32-76.25 .0259
vs ASX 3.87 2.08-7.23 <.0001a
TIA vs TMB 1.92 0.23-16.27 .5476
vs ASX 0.74 0.30-1.85 .5238
TMB ASX 0.39 0.05-2.90 .3549
Stroke outcome Stroke vs TIA 0.97 0.58-1.61 .9050 Controls for age, white race, diabetes, ASA
grade, clopidogrel, and CPD usevs TMB 2.20 0.88-5.47 .0905
vs ASX 2.59 1.60-4.18 <.0001a
TIA vs TMB 2.27 0.94-5.45 .0674
vs ASX 2.67 1.77-4.03 <.0001a
TMB vs ASX 1.18 0.50-2.79 .7102
MI outcome Stroke vs TIA 1.04 0.30-3.58 .9514 Controls for CAD
vs TMB 0.75 0.17-3.42 .7150
vs ASX 1.12 0.38-3.32 .8324
TIA vs TMB 0.73 0.19-2.84 .6461
vs ASX 1.08 0.45-2.57 .8595
TMB vs ASX 1.49 0.44-5.07 .5241
ASA, American Society of Anesthesiologists; ASX, asymptomatic; CAD, coronary artery disease; CI, conﬁdence interval; CPD, cerebral protection device;MI,
myocardial infarction; OR, odds ratio; TIA, transient ischemic attack; TMB, transient monocular blindness.
aP < .0083 considered signiﬁcant after Bonferroni correction for multiple comparisons.
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nature of the enrolled CAS and CEA patient populations
invalidates comparisons between the endovascular and
surgical treatment groups.
After application of the stringent risk-adjusting
methods described before, multiple symptom group com-
parisons were conducted in bivariate fashion, illuminating
the effect of presenting symptom type on each of the major
periprocedural outcomes measures (Tables IV and V). Of
note is that 30-day outcomes of TMB and ASX presenta-
tion are indistinguishable for both CAS and CEA patients.
The signiﬁcant ﬁndings from Tables IV and V regarding
symptom type presentation on periprocedural adverse
event outcomes measure are summarized here.
Composite outcome: Death D stroke D MI
For both CAS and CEA treatment groups, stroke or
TIA presentation predicted a higher risk of this composite
outcome than ASX presentation.Composite outcome: Death D stroke
For both CAS and CEA treatment groups, stroke or
TIA presentation predicted a higher risk than ASX
presentation.
Individual components of the composite outcomes
Death. In the CAS treatment group only, stroke presen-
tation predicted a higher risk than TIA or ASX presentation.
Stroke. For both CAS and CEA treatment groups,
stroke or TIA presentation predicted a higher risk than ASX
presentation, as was reﬂected in the composite outcomes.
MI. No effect of presenting symptom type was noted
on this outcome.
DISCUSSION
These data challenge practitioners to reconsider
whether the binary classiﬁcation of carotid lesions as either
“asymptomatic” or “symptomatic” oversimpliﬁes a more
Table V. Risk-adjusted bivariate comparison of outcomes based on presenting symptom types within the carotid
endarterectomy (CEA) treatment group
CEA: Multivariable (adjusted) logistic models
Ipsilateral symptom
Thirty-day
outcome
Comparison
group
Reference
group OR 95% CI P value Adjusted Covariates
Death/stroke/
MI outcome
Stroke vs TIA 1.30 0.83-2.03 .2466 Controls for age, white race, CAD, diabetes,
ASA grade, and aspirin use
vs TMB 2.56 1.18-5.57 .0174
vs ASX 2.12 1.46-3.08 <.0001a
TIA vs TMB 1.97 0.91-4.25 .0844
vs ASX 1.63 1.14-2.33 .0073a
TMB vs ASX 0.83 0.40-1.72 .6120
Death/stroke
outcome
Stroke vs TIA 1.50 0.93-2.41 .0935 Controls for ASA grade and aspirin use
vs TMB 3.85 1.50-9.91 .0052a
vs ASX 2.73 1.84-4.05 <.0001a
TIA vs TMB 2.56 0.99-6.62 .0517
vs ASX 1.82 1.22-2.72 .0035a
TMB vs ASX 0.71 0.29-1.76 .4598
Death outcome Stroke vs TIA 2.07 0.79-5.41 .1361 Controls for ASA grade and aspirin use
vs ASX 2.10 1.04-4.23 .0388
TIA vs ASX 1.01 0.44-2.32 .9796
Stroke outcome Stroke vs TIA 1.36 0.80-2.32 .2546 Controls for diabetes, TMB, and ASA grade
vs TMB 4.58 1.36-15.42 .0140
vs ASX 2.79 1.77-4.40 <.0001a
TIA vs TMB 3.36 1.01-11.17 .0478
vs ASX 2.05 1.31-3.20 .0016a
TMB vs ASX 0.61 0.19-1.98 .4113
MI outcome Stroke vs TIA 0.51 0.18-1.42 .1972 Controls for age, white race, CAD, and
diabetesvs TMB 0.84 0.20-3.55 .8098
vs ASX 0.67 0.27-1.71 .4041
TIA vs TMB 1.65 0.47-5.83 .4346
vs ASX 1.33 0.73-2.43 .3584
TMB vs ASX 0.80 0.25-2.61 .7156
ASA, American Society of Anesthesiologists; ASX, asymptomatic; CAD, coronary artery disease; CI, conﬁdence interval; MI, myocardial infarction; OR, odds
ratio; TIA, transient ischemic attack; TMB, transient monocular blindness.
aP < .0083 considered signiﬁcant after Bonferroni correction for multiple comparisons.
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that speciﬁc presenting symptom types are powerful predic-
tors of 30-day outcomes for CEA and CAS. In particular,
the broad umbrella of symptomatic carotid disease encom-
passes several presenting symptoms with widely divergent
perioperative risk proﬁles. Familiarity with these additional
prognostic factors may allow clinicians to better counsel pa-
tients about treatment options and expected outcomes.
Are these expected outcomes broadly applicable to the
multiple specialties that engage in performance of CEA and
CAS? In their recent analysis of CREST, Timaran et al15
demonstrated that vascular surgeon outcomes were statisti-
cally similar to those generated by other participating spe-
cialties. Thus, although vascular surgeons represent the
majority of clinicians entering patient data into the SVS-
VR, we expect that the inﬂuence of presenting symptom
type on periprocedural outcomes would be a durable
ﬁnding, regardless of the physician operator.
There are weaknesses of this study that deserve
mention. The cohort of patients presenting with TMB
(n ¼ 508) is less well powered than in the other studygroups, relatively limiting the strength of bivariate compar-
isons in those instances. The SVS-VR data are self-
reported, with inherent potential for bias. In addition,
the CEA and CAS patient groups are unmatched, and
thus direct comparisons between such cohorts must be
conducted with caution, even after concerted efforts at
risk adjustment. For that reason, we have primarily sought
to identify the prognostic signiﬁcance of symptom type
within the separate CAS and CEA treatment groups and
limited comparisons between the therapeutic modalities.
Longer term outcomes data would be desirable, but
beyond the 30-day perioperative period, the SVS-VR
data collection for carotid subjects becomes attenuated.
With regard to risk adjustment techniques, we strove to
maximally risk adjust these populations before engaging in
bivariate comparisons (Tables IV and V). The rationale for
not using a cerebral protection device (CPD) is often not
found within the SVS-VR. Thus, the reviewer cannot reli-
ably determine whether failure to use a CPD was secondary
to the elective choice of the interventionalist or due to
anatomic constraints that rendered CPD use impossible.
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use a CPD. The refusal or inability to use a CPD was asso-
ciated with higher risk of stroke (11.3% vs 4.6 % with CPD
use; P ¼ .009). As we could not be certain whether CPD
nonuse was elective or mandated by anatomy, we chose
to risk adjust for CPD use in these analyses; that decision
may have introduced bias favoring the outcomes of CAS.
In light of the higher adverse event rates seen when
CPDs were not used for CAS, CEA should be preferen-
tially employed when this constraint is anticipated.
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